“The Buzz” Show: Gilead (NASDAQ: GILD) Receives FDA Approval for COVID-19 Treatment | Financial Buzz

“The Buzz” Show: Gilead (NASDAQ: GILD) Receives FDA Approval for COVID-19 Treatment

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Gilead Receives FDA Approval for COVID-19 Treatment”

Gilead Sciences, Inc. (NASDAQ: GILD) opened 4% higher after announcing that its COVID-19 treatment was granted FDA approval.

The antiviral drug, Ramdesivir, is the first treatment to receive FDA approval and is said to shorten the recovery time of patients already hospitalized.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information, please visit: Gilead Sciences, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.